Current Report Filing (8-k)
October 17 2018 - 4:54PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
October 17, 2018
(
October 11, 2018)
Heyu
Biological Technology Corporation
(Exact Name of Registrant as Specified in its
Charter)
Nevada
|
|
000-26731
|
|
87-0627910
|
(State or Other Jurisdiction of
Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
4th Floor, No. 10 Building, Xinglin Bay Business
Operation Center,
Jimei District, Xiamen City,
Fujian Province, China 361022
(Address of Principal Executive Offices, Zip
Code)
Registrant’s telephone number, including
area code:
(86) 158 5924 0902
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
As of October 11,
2018, Heyu Biological Technology Corporation (the “Company”) is currently nearing the completion of an on-site due
diligence investigation of both the financial and legal aspects of Fujian Shanzhiling Biological Technology Co., Ltd (the “Acquirer”).
The due diligence investigation is done pursuant to the non-binding letter of intent entered into between the Company and the Acquirer
on October 8, 2018, whereby the Acquirer has agreed to acquire 51 percent (51%) of the outstanding capital of the Company subject
to certain adjustment provisions (the “Acquisition”). The Company and the Acquirer are in the final phase of negotiations
and are working to close the Acquisition as soon as possible.
As of the date of this current report,
there is no definitive agreement entered into between the Company and the Acquirer and there is no assurance the aforementioned
transaction will be consummated.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Company has duly caused this Report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Heyu Biological Technology Corporation
|
|
|
|
By:
|
/s/
Ban Siong Ang
|
|
Name:
Title:
|
Ban Siong Ang
Chief Executive Officer
|
|
|
|
|
Dated:
|
October 17, 2018
|
Heyu Biological Technology (PK) (USOTC:HYBT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Heyu Biological Technology (PK) (USOTC:HYBT)
Historical Stock Chart
From Jul 2023 to Jul 2024